Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease

被引:36
|
作者
Ho, Jean K. [1 ]
Nation, Daniel A. [1 ]
机构
[1] Univ Southern Calif, Dept Psychol, 3620 South McClintock Ave, Los Angeles, CA 90089 USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
Alzheimer's disease; Amyloid beta; Tau; Biomarkers; Cognition; Memory; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; RISK-FACTOR; DECLINE; PATHOPHYSIOLOGY; RECOMMENDATIONS; NEURODEGENERATION; INDIVIDUALS;
D O I
10.1017/S135561771800022X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The present study investigated the independent and synergistic effects of amyloid beta (A beta(1-42)) and phosphorylated tau (Ptau) pathologies on neuropsychological profiles and trajectories in cognitively normal older adults. Methods: Alzheimer's Disease Neuroimaging Initiative participants identified as cognitively normal at baseline underwent longitudinal assessment (N= 518; 0, 12, 24, 36 months), baseline lumbar puncture and follow-up cognitive exams. Cerebral spinal fluid (CSF) biomarker profiles (A beta-Ptau-, A beta+Ptau-, A beta-Ptau+, A beta+Ptau+) were compared on baseline profiles and trajectories for memory (Rey Auditory Verbal Learning Test), attention/executive function (Trail Making Test, A and B), language (Animal Fluency, Vegetable Fluency, Boston Naming Test) and processing speed (Digit Symbol) using multilevel models. Results: The A beta+Ptau+ group exhibited significantly worse baseline performance on tests of memory and executive function relative to the A beta-Ptau+ and A beta-Ptau- groups. The A beta+Ptau- group fell between the A beta+Ptau+ participants and the A beta-Ptau- and A beta-Ptau+ groups on all three cognitive domains and exhibited worse baseline executive function. The A beta-Ptau+ group performed worse than A beta-Ptau- participants on processing speed. Over 36-month follow-up, the A beta+Ptau+ group exhibited the greatest declines in memory and semantic fluency compared to all other groups. Conclusions: Cognitively normal older adults with both A beta and Ptau pathology exhibited the weakest profile, marked by the worst memory decline compared to the other groups. Other subtle changes in this group included declines in executive function and semantic fluency. Those with Ptau pathology alone showed slowed processing speed, and those with A beta pathology alone showed worse attention and executive function compared to biomarker negative participants.
引用
收藏
页码:693 / 702
页数:10
相关论文
共 50 条
  • [1] Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease
    Yakoub, Yara J.
    Ashton, Nicholas
    Strikwerda-Brown, Cherie
    Montoliu-Gaya, Laia K.
    Karikari, Thomas
    Kac, Przemyslaw R.
    Gonzalez-Ortiz, Fernando
    Gallego-Rudolf, Jonathan
    Meyer, Pierre-Francois
    St-Onge, Frederic
    Schoell, Michael
    Soucy, Jean-Paul
    Breitner, John C. S.
    Zetterberg, Henrik
    Blennow, Kaj
    Poirier, Judes
    Villeneuve, Sylvia
    ALZHEIMERS & DEMENTIA, 2023, : 5620 - 5631
  • [2] Neurophysiological trajectories in Alzheimer's disease progression
    Kudo, Kiwamu
    Ranasinghe, Kamalini G.
    Morise, Hirofumi
    Syed, Faatimah
    Sekihara, Kensuke
    Rankin, Katherine P.
    Miller, Bruce L.
    Kramer, Joel H.
    Rabinovici, Gil D.
    Vossel, Keith
    Kirsch, Heidi E.
    Nagarajan, Srikantan S.
    ELIFE, 2024, 12
  • [3] Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
    Wang, Hui-Fu
    Shen, Xue-Ning
    Li, Jie-Qiong
    Suckling, John
    Tan, Chen-Chen
    Wang, Yan-Jiang
    Feng, Lei
    Zhang, Can
    Tan, Lan
    Dong, Qiang
    Touchon, Jacques
    Gauthier, Serge
    Yu, Jin-Tai
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)
  • [4] Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases
    Hessen, Erik
    Stav, Ane Lovli
    Auning, Eirik
    Selnes, Per
    Blomso, Linn
    Holmeide, Cathrine Emilie
    Johansen, Krisztina Kunszt
    Eliassen, Carl Fredrik
    Reinvang, Ivar
    Fladby, Tormod
    Aarsland, Dag
    JOURNAL OF PARKINSONS DISEASE, 2016, 6 (02) : 413 - 421
  • [5] Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease
    Schindler, Suzanne E.
    Jasielec, Mateusz S.
    Weng, Hua
    Hassenstab, Jason J.
    Grober, Ellen
    Mccue, Lena M.
    Morris, John C.
    Holtzman, David M.
    Xiong, Chengjie
    Fagan, Anne M.
    NEUROBIOLOGY OF AGING, 2017, 56 : 25 - 32
  • [6] On the path to 2025: understanding the Alzheimer's disease continuum
    Aisen, Paul S.
    Cummings, Jeffrey
    Jack, Clifford R., Jr.
    Morris, John C.
    Sperling, Reisa
    Froelich, Lutz
    Jones, Roy W.
    Dowsett, Sherie A.
    Matthews, Brandy R.
    Raskin, Joel
    Scheltens, Philip
    Dubois, Bruno
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [7] The critical need for defining preclinical biomarkers in Alzheimer's disease
    Fiandaca, Massimo S.
    Mapstone, Mark E.
    Cheema, Amrita K.
    Federoff, Howard J.
    ALZHEIMERS & DEMENTIA, 2014, 10 (03) : S196 - S212
  • [8] Internal Consistency Over Time of Subjective Cognitive Decline: Drawing Preclinical Alzheimer's Disease Trajectories
    Avila-Villanueva, Marina
    Maestu, Fernando
    Fernandez-Blazquez, Miguel A.
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 66 (01) : 173 - 183
  • [9] P-tau235: a novel biomarker for staging preclinical Alzheimer's disease
    Lantero-Rodriguez, Juan
    Snellman, Anniina
    Benedet, Andrea L.
    Mila-Aloma, Marta
    Camporesi, Elena
    Montoliu-Gaya, Laia
    Ashton, Nicholas J.
    Vrillon, Agathe
    Karikari, Thomas K.
    Gispert, Juan Domingo
    Salvado, Gemma
    Shekari, Mahnaz
    Toomey, Christina E.
    Lashley, Tammaryn L.
    Zetterberg, Henrik
    Suarez-Calvet, Marc
    Brinkmalm, Gunnar
    Rosa Neto, Pedro
    Blennow, Kaj
    EMBO MOLECULAR MEDICINE, 2021, 13 (12)
  • [10] Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study
    Ma, Ling-Zhi
    Tan, Lan
    Bi, Yan-Lin
    Shen, Xue-Ning
    Xu, Wei
    Ma, Ya-Hui
    Li, Hong-Qi
    Dong, Qiang
    Yu, Jin-Tai
    MOLECULAR NEURODEGENERATION, 2020, 15 (01)